Metalloproteinases in Inflammatory Bowel Diseases

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2021 Apr 1

PMID 33790618

Citations 28

Authors

Martin Maronek

Irene Marafini

Roman Gardlik

Rene Link

Edoardo Troncone

Giovanni Monteleone

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the gastrointestinal tract, encompassing two main disorders: Crohn's disease (CD) and ulcerative colitis (UC). In both these pathologies, excessive and local immune response against luminal antigens promotes a pathological process leading to various degrees of gut damage. Matrix metalloproteinases (MMPs) are a family of neutral proteases with the ability to degrade all components of extracellular matrix. In physiological conditions, MMPs are produced at very low level and generally in the latent form and are involved in the normal tissue turnover. Their function is inhibited by tissue inhibitors of metalloproteinases (TIMPs). However, in inflamed tissue of IBD patients, MMPs are produced in excess and/or the activity of TIMPs is not sufficient to block MMPs, thereby making a major contribution to the IBD-related mucosal degradation. In this review, we summarize the available evidence on the expression and role of MMPs in IBD.

Citing Articles

Follicular Skin Disorders, Inflammatory Bowel Disease, and the Microbiome: A Systematic Review.

Fleshner L, Roster K, Farabi B, Hirani R, Tepper K, Pitchumoni C Int J Mol Sci. 2024; 25(18).

PMID: 39337688 PMC: 11431962. DOI: 10.3390/ijms251810203.

Infliximab in Inflammatory Bowel Disease: Leveraging Physiologically Based Pharmacokinetic Modeling in the Clinical Context.

Petric Z, Goncalves J, Paixao P Biomedicines. 2024; 12(9).

PMID: 39335488 PMC: 11429320. DOI: 10.3390/biomedicines12091974.

Anti-Inflammatory Effect of Dietary Pentadecanoic Fatty Acid Supplementation on Inflammatory Bowel Disease in SAMP1/YitFc Mice.

Singh D, Mehghini P, Rodriguez-Palacios A, Di Martino L, Cominelli F, Basson A Nutrients. 2024; 16(17).

PMID: 39275347 PMC: 11397537. DOI: 10.3390/nu16173031.

Identification of a Novel Activated NK-Associated Gene Score Associated with Diagnosis and Biological Therapy Response in Ulcerative Colitis.

Dong S, Zhang Y, Ye L, Cao Q Digestion. 2024; 106(1):1-22.

PMID: 39182484 PMC: 11825133. DOI: 10.1159/000540939.

Perianal Fistula; from Etiology to Treatment - A Review.

Sohrabi M, Bahrami S, Mosalli M, Khaleghian M, Obaidinia M Middle East J Dig Dis. 2024; 16(2):76-85.

PMID: 39131109 PMC: 11316198. DOI: 10.34172/mejdd.2024.373.

References

Biancheri P, Brezski R, Di Sabatino A, Greenplate A, Soring K, Corazza G . Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology. 2015; 149(6):1564-1574.e3. DOI: 10.1053/j.gastro.2015.07.002. View

Gordon J, Pickard K, Di Sabatino A, Prothero J, Pender S, Goggin P . Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflamm Bowel Dis. 2007; 14(2):195-203. DOI: 10.1002/ibd.20302. View

Schuppan D, Freitag T . Fistulising Crohn's disease: MMPs gone awry. Gut. 2004; 53(5):622-4. PMC: 1774058. DOI: 10.1136/gut.2003.034207. View

Monteleone G, Monteleone I, Fina D, Vavassori P, Del Vecchio Blanco G, Caruso R . Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology. 2005; 128(3):687-94. DOI: 10.1053/j.gastro.2004.12.042. View

Pender S, Tickle S, Docherty A, Howie D, Wathen N, MacDonald T . A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol. 1997; 158(4):1582-90. View

Pender S, Braegger C, Gunther U, Monteleone G, Meuli M, Schuppan D . Matrix metalloproteinases in necrotising enterocolitis. Pediatr Res. 2003; 54(2):160-4. DOI: 10.1203/01.PDR.0000072326.23442.C3. View

Monteleone G, Parrello T, Luzza F, Pallone F . Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7. Gut. 1998; 43(5):620-8. PMC: 1727325. DOI: 10.1136/gut.43.5.620. View

Lin X, Li J, Zhao Q, Feng J, Gao Q, Nie J . WGCNA Reveals Key Roles of IL8 and MMP-9 in Progression of Involvement Area in Colon of Patients with Ulcerative Colitis. Curr Med Sci. 2018; 38(2):252-258. DOI: 10.1007/s11596-018-1873-6. View

Sykes A, Bhogal R, Brampton C, Chander C, Whelan C, Parsons M . The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther. 1999; 13(11):1535-42. DOI: 10.1046/j.1365-2036.1999.00633.x. View

10.

Biancheri P, Di Sabatino A, Corazza G, Macdonald T . Proteases and the gut barrier. Cell Tissue Res. 2012; 351(2):269-80. DOI: 10.1007/s00441-012-1390-z. View

11.

Altadill A, Eiro N, Gonzalez L, Junquera S, Gonzalez-Quintana J, Sanchez M . Comparative analysis of the expression of metalloproteases and their inhibitors in resected crohn's disease and complicated diverticular disease. Inflamm Bowel Dis. 2011; 18(1):120-30. DOI: 10.1002/ibd.21682. View

12.

Kucukguven A, Khalil R . Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets. 2013; 14(3):287-324. PMC: 3584231. View

13.

Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F . Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997; 112(4):1169-78. DOI: 10.1016/s0016-5085(97)70128-8. View

14.

Rath T, Roderfeld M, Halwe J, Tschuschner A, Roeb E, Graf J . Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. Scand J Gastroenterol. 2010; 45(10):1186-96. DOI: 10.3109/00365521.2010.499961. View

15.

Sandborn W, Targan S . Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002; 122(6):1592-608. DOI: 10.1053/gast.2002.33426. View

16.

Wang Y, Tan X, Zhang K . Correlation of plasma MMP-1 and TIMP-1 levels and the colonic mucosa expressions in patients with ulcerative colitis. Mediators Inflamm. 2009; 2009:275072. PMC: 2774532. DOI: 10.1155/2009/275072. View

17.

Macdonald T, Monteleone G . Immunity, inflammation, and allergy in the gut. Science. 2005; 307(5717):1920-5. DOI: 10.1126/science.1106442. View

18.

Schreiber S, Siegel C, Friedenberg K, Younes Z, Seidler U, Bhandari B . A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease. J Crohns Colitis. 2018; 12(9):1014-1020. PMC: 6113705. DOI: 10.1093/ecco-jcc/jjy070. View

19.

Dunsmore S, Roby J, Wilson C, Matrisian L, Welgus H, Parks W . Matrilysin expression and function in airway epithelium. J Clin Invest. 1998; 102(7):1321-31. PMC: 508979. DOI: 10.1172/JCI1516. View

20.

Pender S, Li C, di Sabatino A, Sabatino A, MacDonald T, Buckley M . Role of macrophage metalloelastase in gut inflammation. Ann N Y Acad Sci. 2006; 1072:386-8. DOI: 10.1196/annals.1326.019. View